Cargando…
Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians
Mycobacterium chimaera, a member of the Mycobacterium avium complex, can cause infections in individuals after open heart surgery due to contaminated heater-cooler units. The diagnosis can be challenging, as the incubation period can be quite variable, and symptoms are nonspecific. In addition to ag...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297092/ https://www.ncbi.nlm.nih.gov/pubmed/35866101 http://dx.doi.org/10.1093/ofid/ofac287 |
_version_ | 1784750404961042432 |
---|---|
author | Mason, Matt Gregory, Eric Foster, Keith Klatt, Megan Zoubek, Sara Eid, Albert J |
author_facet | Mason, Matt Gregory, Eric Foster, Keith Klatt, Megan Zoubek, Sara Eid, Albert J |
author_sort | Mason, Matt |
collection | PubMed |
description | Mycobacterium chimaera, a member of the Mycobacterium avium complex, can cause infections in individuals after open heart surgery due to contaminated heater-cooler units. The diagnosis can be challenging, as the incubation period can be quite variable, and symptoms are nonspecific. In addition to aggressive surgical management, combination pharmacologic therapy is the cornerstone of therapy, which should consist of a macrolide, a rifamycin, ethambutol, and amikacin. Multiple second-line agents may be utilized in the setting of intolerances or toxicities. In vitro susceptibility of these agents is similar to activity against other species in the Mycobacterium avium complex. Drug–drug interactions are frequently encountered, as many individuals have chronic medical comorbidities and are prescribed medications that interact with the first-line agents used to treat M. chimaera. Recognition of these drug–drug interactions and appropriate management are essential for optimizing treatment outcomes. |
format | Online Article Text |
id | pubmed-9297092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-92970922022-07-20 Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians Mason, Matt Gregory, Eric Foster, Keith Klatt, Megan Zoubek, Sara Eid, Albert J Open Forum Infect Dis Review Article Mycobacterium chimaera, a member of the Mycobacterium avium complex, can cause infections in individuals after open heart surgery due to contaminated heater-cooler units. The diagnosis can be challenging, as the incubation period can be quite variable, and symptoms are nonspecific. In addition to aggressive surgical management, combination pharmacologic therapy is the cornerstone of therapy, which should consist of a macrolide, a rifamycin, ethambutol, and amikacin. Multiple second-line agents may be utilized in the setting of intolerances or toxicities. In vitro susceptibility of these agents is similar to activity against other species in the Mycobacterium avium complex. Drug–drug interactions are frequently encountered, as many individuals have chronic medical comorbidities and are prescribed medications that interact with the first-line agents used to treat M. chimaera. Recognition of these drug–drug interactions and appropriate management are essential for optimizing treatment outcomes. Oxford University Press 2022-06-15 /pmc/articles/PMC9297092/ /pubmed/35866101 http://dx.doi.org/10.1093/ofid/ofac287 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Review Article Mason, Matt Gregory, Eric Foster, Keith Klatt, Megan Zoubek, Sara Eid, Albert J Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians |
title | Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians |
title_full | Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians |
title_fullStr | Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians |
title_full_unstemmed | Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians |
title_short | Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians |
title_sort | pharmacologic management of mycobacterium chimaera infections: a primer for clinicians |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297092/ https://www.ncbi.nlm.nih.gov/pubmed/35866101 http://dx.doi.org/10.1093/ofid/ofac287 |
work_keys_str_mv | AT masonmatt pharmacologicmanagementofmycobacteriumchimaerainfectionsaprimerforclinicians AT gregoryeric pharmacologicmanagementofmycobacteriumchimaerainfectionsaprimerforclinicians AT fosterkeith pharmacologicmanagementofmycobacteriumchimaerainfectionsaprimerforclinicians AT klattmegan pharmacologicmanagementofmycobacteriumchimaerainfectionsaprimerforclinicians AT zoubeksara pharmacologicmanagementofmycobacteriumchimaerainfectionsaprimerforclinicians AT eidalbertj pharmacologicmanagementofmycobacteriumchimaerainfectionsaprimerforclinicians |